Omar Nadeem

13PUBLICATIONS

151CO-AUTHORS

Haematological tumoursMedical infection agents (incl. prions)Epidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteins

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 03, 2026

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

|Apr 27, 2026

Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study.

|Apr 21, 2026

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

|Apr 20, 2026

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

|Apr 08, 2026

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Omar Nadeem, Michelle P Aranha, Robert A Redd

|Mar 28, 2026

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

Pageof 3

Frequent Collaborators

Irene M Ghobrial

Adam S Sperling

Shonali Midha

Larry D Anderson

Gad Getz

Shebli Atrash

Danai Dima

Aimaz Afrough

Rahul Banerjee

Andrew J Portuguese

Frequent Collaborators

Irene M Ghobrial

Adam S Sperling

Shonali Midha

Larry D Anderson